From GlobeNewswire: 2025-03-27 12:45:00

Transgene, a biotech company, achieved clinical proof of principle in a Phase I trial for individualized cancer vaccine TG4050 in head and neck cancer. Positive 24-month follow-up data expected in Q2 2025. Phase II trial in progress. New trial planned in a second indication by Q4 2025. Company funded until April 2026.
Financial results for 2024 show €6.4 million in operating revenue, with €42 million in net operating expenses. Net loss for 2024 was €34 million. Company funded until April 2026 with new agreement. Leadership team focused on accelerating innovative immunotherapy portfolio. Conference call scheduled today at 6 p.m. CET.
Key events in 2024 include progress in individualized cancer vaccine program, with positive results in Phase I trial. Randomized Phase I/II trial demonstrated disease-free status in patients. Phase II trial in head and neck cancer ongoing. New Phase I trial planned for second indication in Q4 2025.



Read more at GlobeNewswire:: Transgene Achieves Key Milestones in 2024, Including